Summary of ‘A randomized controlled trial of the outcomes of Arista™ hemostatic agent in robotic ventral hernia repair’
SPONSORED ARTICLE
Arista™ Hemostatic Agent in Hernia Surgery: Impact on Drain Output and Postoperative Complications
Ventral hernia repairs (VHR) account for a significant number of surgical procedures in the United States, with over 300,000 cases performed annually. The rise of robotic-assisted surgery has improved the safety and efficacy of these procedures, particularly through techniques like myofascial release. However, the complex dissection involved may lead to postoperative complications, including seromas and hematomas.
This study evaluates the effectiveness of Arista™ hemostatic agent, FDA-approved , in reducing these complications during robotic-assisted laparoscopic VHR, particularly when mesh is placed in the retrorectus space.
Methods
A single-institution, single-blind, prospective randomized controlled trial was conducted at a tertiary referral center, enrolling 100 patients undergoing elective robotic-assisted laparoscopic VHR. Participants were randomly assigned to receive either 5 g of Arista™ or standard care without a hemostatic agent.
Primary Outcomes:
- Drain output on postoperative day 1
- Total drain output
- Duration of drain placement
Secondary Outcomes:
- Estimated blood loss (EBL)
- Number of drains used
- Operative time
- Length of hospital stay (LOS)
Results
The findings revealed that total drain output was significantly higher in the Arista™ group (592.8 ml) compared to the control group (407.9 ml), marking a 39.6% increase (p = 0.01). However, no significant differences were observed in drain output on postoperative day 1 or the duration of drain placement.
Secondary outcomes, including EBL, number of drains used, operative time, and LOS, showed no statistically significant differences between the two groups. Importantly, no cases of seromas, hematomas, or surgical site infections were reported in either group during short-term follow-up.
Discussion
The use of Arista™ as a hemostatic agent in hernia surgery resulted in increased total postoperative drain output, yet did not significantly impact other surgical outcomes. These findings underscore the prevalence of postoperative fluid collections in VHR and suggest that Arista™ may contribute to total fluid output without reducing seroma or hematoma risk.
The lack of significant differences in secondary outcomes highlights the need for further research to determine whether Arista™ provides specific benefits for certain patient subsets or surgical techniques.
Conclusion
In conclusion, the application of Arista™ in robotic-assisted laparoscopic VHR was associated with a higher total drain output but did not affect blood loss, drain duration, hospital stay, or the number of drains used. These findings emphasize the necessity for additional studies exploring the role of Arista™ in different hernia types and patient populations.
READ MORE… https://link.springer.com/article/10.1007/s11701-025-02252-1
